Wie hoch ist der Preis für Novo Nordisk A/S (NOVO-B)

Preis für Novo Nordisk A/S (NOVO-B) ist $44.39

Wie hoch ist die Marktkapitalisierung für Novo Nordisk A/S (NOVO-B)

Marktkapitalisierung für Novo Nordisk A/S (NOVO-B) ist $197.21B

Novo Nordisk A/S (NOVO-B) Operative Marge

Novo Nordisk A/S operates as a global healthcare enterprise, dedicated to the innovation, development, production, and commercialization of pharmaceutical solutions. Its business is primarily divided into two key segments: Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity Care segment offers a comprehensive portfolio of treatments for diabetes (including insulins, GLP-1 analogues, oral antidiabetic agents, and related delivery systems), obesity management, glucagon, medical needles, and other chronic conditions. The Rare Disease segment provides specialized medications for haemophilia, various blood disorders, endocrine imbalances, growth hormone deficiencies, and hormone replacement therapy. Additionally, the company engages in strategic alliances, including a partnership with Gilead Sciences, Inc., and conducts research focused on identifying cell-specific carriers for nucleic acid-based therapies. Established in 1923, Novo Nordisk A/S is headquartered in Bagsvaerd, Denmark.

Jahr	Operative Marge	ändert
Nicht genügend Daten für die angegebenen Daten.

Jahr

Operative Marge

ändert

Nicht genügend Daten für die angegebenen Daten.

Unternehmen	Operative Marge	Differenz der operativen Marge	Land
Eli Lilly and Company LLY.US	43.92%	-98.96%	US
Johnson & Johnson JNJ.US	26.81%	-99.36%	US
AbbVie Inc. ABBV.US	29.32%	-99.30%	US
Roche Holding AG RO.SW	26.59%	-99.37%	CH
Merck & Co., Inc. MRK.US	16.65%	-99.60%	US

Unternehmen

Operative Marge

Differenz der operativen Marge

Land